Because we have engineered the size of the PolyhHb to reduce Hb extravasation mediated side effects, the therapeutic benefits of our PolyhHbs are likely coupled to perfusion in the tumor microcirculatory system. This evidence concerns the gene GSTM1 and neoplasm.